23 / 27
Real World Data
Berdelou A, et al. Thyroid. 2017
• 1L vs 2L: Efficacy and Safety Indicators
Objective
To describe the
efficacy and the toxicity profile of Lenvatinib in real life
during the ATU Program.
Patients and methods
•
Only 17 patients (23%) would have been eligible for inclusion in the SELECT phase 3 trial
. The
other patients would have been excluded for because of:
ECOG performance status ≥2 (12),
uncontrolled HTN (>140/80) (7), haemoptysis (3), prostatic cancer not in remission (1), cutaneous
fistula of a bone metastasis (1), not focal treatment for brain metastasis (3/9).
•
Patients had received more than one systemic treatment with MKI before LEN (18).
Results
•
Efficacy
data after a median follow-up of 7 months (range, 0.4–14.6) after the initiation of LEN Tx.
Parameter
Results
Median DOT, mo (range)
6 (0.1 - 15)
Median time to first dose reduction, mo
2.1
Median treatment dose, mg/day
20